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Abstract
Background The Zwolle Risk Score (ZRS) identifies pri-
mary percutaneous coronary intervention (PPCI) patients at
low mortality risk, eligible for early discharge. Recently,
this score was improved by adding baseline NT-proBNP.
However, the optimal timepoint for NT-proBNP measure-
ment is unknown.
Methods PPCI patients in the On-Time 2 study were can-
didates. The ZRS and NT-proBNP levels on admission,
at 18–24 h, at 72–96 h, and the change in NT-proBNP
from baseline to 18–24 h (delta NT-proBNP) were deter-
mined. We investigated whether addition of the different
NT-proBNP measurements to the ZRS improves the predic-
tion of 30-day mortality. Based on cut-off values reflecting
zero mortality at 30 d, patients who potentially could be
discharged early were identified and occurrence of major
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adverse cardiac events (MACE) and major bleeding until
10 d was registered.
Results 845 patients were included. On multivariate analy-
ses, NT-proBNP at baseline (HR 2.09, 95% CI 1.59–2.74,
p < 0.001), at 18–24 h (HR 6.83, 95% CI 2.94–15.84), and
at 72–96 h (HR 3.32, 95% CI 1.22–9.06) independently pre-
dicted death at 30 d. Addition of NT-proBNP to the ZRS
improved prediction of mortality, particularly at 18–24 h
(net reclassification index 29%, p < 0.0001, integrated dis-
crimination improvement 17%, p < 0.0001). Based on ZRS
(<2) or NT-proBNP at 18–24 h (<2500 pg/ml) 75% of pa-
tients could be targeted for early discharge at 48 h, with
expected re-admission rates of 1.2% due to MACE and/or
major bleeding.
Conclusions NT-proBNP at different timepoints improves
prognostication of the ZRS. Particularly at 18–24 h post
PPCI, the largest group of patients that potentially could be
discharged early was identified.
Keywords STEMI · Serial NT-proBNP · PPCI · Zwolle
Risk Score · Early discharge · Major adverse cardiac
events (MACE)
Introduction
Primary percutaneous coronary intervention (PPCI) sub-
stantially improved outcome in patients with ST-elevation
myocardial infarction (STEMI), which has been paralleled
by a decrease in hospital length of stay [1–3]. In addition
several studies have demonstrated that most low-risk PPCI
patients are eligible candidates for early discharge [4–11].
The Zwolle Risk Score (ZRS) is a simple tool designed to
identify PPCI patients who can be safely discharged within
72 h, based on their 30-day mortality risk [11]. In patients
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Fig. 1 Zwolle Risk Score (a)
and relative risk (RR) of 30-day
mortality for each score (b)
(CI confidence interval,
STEMI ST-elevation myocardial
infarction, TIMI Thrombolysis
in Myocardial Infarction)
with a score 3 (low risk) the mortality rate was 0.1%
at 2 d and 0.2% between 2–10 d and early discharge be-
tween 48–72 h could be applied in slightly more than 60%
of patients (Fig. 1). Recently, we demonstrated that the
predictive accuracy of the ZRS was improved by adding
baseline NT-proBNP [12]. In this report we studied the
value of NT-proBNP measurement at different timepoints
over and beyond the ZRS.
Methods
Patients Our study population consists of patients with
the diagnosis of STEMI admitted for PPCI, who were in-
cluded in the Ongoing Tirofiban in Myocardial Infarction
Evaluation (On-TIME) 2 trial [13]. The rationale, design
and primary results of this multicentre placebo-controlled,
randomised clinical trial have been previously described
[13, 14].
Briefly, enrolment was from June 2006 to November
2007. Eligible patients were aged 21–85 years with symp-
toms of acute myocardial infarction of more than 30 min
but less than 24 h and ST-segment elevation of more than
1 mV in two adjacent electrocardiograph (ECG) leads. Ex-
clusion criteria were severe renal dysfunction (glomerular
filtration rate <30 ml/min or serum creatinine >200 mmol/l
(>2.5 mg/dl)), therapy-resistant cardiogenic shock (systolic
blood pressure 80 mm Hg for >30 min), persistent severe
hypertension (systolic blood pressure >180 mm Hg or di-
astolic blood pressure >110 mm Hg), or a contraindication
to anticoagulation, or increased risk of bleeding. Also, pa-
tients with left bundle branch block, pregnant and/or breast-
feeding women, and patients with a life expectancy of less
than one year were excluded. Written informed consent for
participation in both the On-TIME 2 study and future data
analysis was obtained from each patient. All local ethics
committees involved approved the study protocol.
Procedures
Treatment
All patients were planned to undergo PPCI and were ini-
tially treated according to the study protocol, randomly as-
signed to (prehospital) treatment with tirofiban (25 µg/kg
bolus and 0.15 µg/kg/min maintenance infusion for 18 h)
or placebo. PPCI was performed with standard techniques
if the coronary anatomy was suitable for angioplasty. All
patients were treated with optimal drug therapy. Final dis-
charge and duration at admission was at the discretion of
the treating cardiologist, irrespective of NT-proBNP values
or ZRS.
Measurements
NT-proBNP plasma levels were measured in each patient
on admission (after sheath insertion), at 18–24 h and at
72–96 h after PPCI.
Neth Heart J (2017) 25:243–249 245
Table 1 Baseline characteristics of the study group
Variable Total (n = 845) %
Age (years) mean ± SD 62.0 ± 11.5 –
Male gender 642 (76.0)
Current smoking 409 (48.4)
Diabetes mellitus 90 (10.7)
Hypertension 282 (33.4)
Hypercholesterolaemia 222 (26.3)
Family history 340 (40.2)
Prior angina 104 (12.4)
Previous MI 69 (8.2)
Previous PTCA 70 (8.3)
Previous CABG 12 (1.4)
Previous CVA 15 (1.8)
Systolic BP, mean ± SD 130.70 ± 24.21 –
Diastolic BP, mean ± SD 76.57 ± 15.03 –
Killip > I 41 (4.9)
Haemoglobin (mmol/l), mean ± SD 9.49 ± 7.16 –
Troponin (μg/l), mean ± SD 0.37 ± 1.24 –
Zwolle Risk Score, mean ± SD 2.34 ± 2.13 –
Hospital stay (days) mean ± SD 4.89 ± 5.64 –
EF < 30% 41 (6.2)
EF 30–40% 130 (19.8)
EF > 40% 486 (74.0)
All values were denoted as mean ± SD or absolute numbers and their
percentages of the total group, where appropriate
MI myocardial infarction, PTCA percutaneous transluminal
coronary angioplasty, CABG coronary artery bypass grafting,
CVA cerebrovascular accident, BP blood pressure, EF ejection fraction
NT-proBNP plasma levels were measured by an electro-
chemiluminiscence immunoassay ‘ECLIA’ on an Elecsys
2010 analyser (Roche, Central Haematology Laboratory,
University of Heidelberg, Germany). The ZRS was calcu-
lated afterwards in each patient.
Endpoints
Endpoints were chosen by the ability to preclude early and
safe discharge. We took two periods of time: at 48 h (after
2 d) and at 96 h after PPCI (after 3 d as recommended in
present guidelines) [1, 2].
The primary endpoint was death from any cause at 30 d
after withdrawal of blood from which the NT-proBNP
level was determined. Secondary endpoints were non-fatal
major adverse cardiac events (MACE) and major bleeding
until 10 d after admission. MACE was defined as recurrent
myocardial infarction, urgent target vessel revascularisation
and malignant cardiac arrhythmias occurring later than 24 h
after PPCI, defined as ventricular fibrillation or sustained
and non-sustained ventricular tachycardia. Major bleeding
was defined as either intracranial bleeding or overt bleeding
with a decrease in haemoglobin ≥5 g/dl (≥3.1 mmol/l) or
a decrease in haematocrit ≥15%.
Statistical analysis
Patients were categorised by percentiles of NT-proBNP lev-
els. We assessed the predictive value of the ZRS, serial NT-
proBNP levels and the absolute change of NT-proBNP lev-
els from baseline to 18–24 h (delta NT-proBNP) for the
primary endpoint.
We computed and plotted receiver operating characteris-
tic (ROC) curves. A total of 74 patients had missing ZRS
values and 36 patients did not have baseline NT-proBNP
levels. Three patients had missing values of both ZRS and
baseline NT-pro BNP. A multiple missing value imputa-
tion procedure was applied in which the values of the NT-
proBNP levels and the values of the elements of the ZRS
were imputed in case they were missing.
We generated 10 datasets and the results of all statistical
analyses were pooled across the 10 datasets. Multivariate
Cox regression analysis was used to estimate the influence
of NT-proBNP and ZRS on 30-day mortality. We adjusted
for randomisation, gender, age, renal function (estimated
glomerular filtration rate in ml/min), and body mass index
in a backward Cox regression with a p-value of 0.05 for
entry or exit of the variables in the model.
We computed the net reclassification index (NRI) and
the integrated discrimination improvement (IDI) to evalu-
ate models with an extra predictor relative to a model with
the ZRS alone [15]. The IDI combines the increase in mor-
tality probability for those experiencing an event plus the
decrease in mortality probability for those not experiencing
an event. The NRI quantifies the net proportion of subjects
being correctly reclassified to low or high mortality proba-
bilities when adding a predictor to the model using a cut-
off point of 30%.
To analyse models using a linear combination of ZRS
and NT-proBNP, we calculated weighted scores for each as
follows: (β1 * ZRS) + (β2 * ln NT-proBNP), where β1 and
β2 denote β-coefficients for the ZRS and log NT-proBNP
obtained from the multivariate Cox regression model. We
used ROC curves to define optimal cut-off values in esti-
mating mortality outcomes. We calculated the pooled ar-
eas under the curve (AUC) and 95% confidence intervals
by averaging over the 10 AUCs from the imputed datasets
using Rubin’s rule [16]. The cut-off values and scores for
defining possible early discharge were obtained from the
mean scores across the 10 datasets, which gave the high-
est specificity in combination with a 100% sensitivity for
the primary endpoint (e. g. zero mortality 30 d after PPCI).
A two-sided p-value of 0.05 was considered to be statis-
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Table 2 Univariate and multivariate Cox proportional hazards analyses for 30-day mortality
NT-proBNP baseline
(n = 845)
NT-proBNP 18–24 h
(n = 786)
NT-proBNP 72–96 h
(n = 768)
Variables P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI)
Univariate analysis
Randomisation placebo vs. tirofiban 0.011 4.10
(1.38–12.19)
0.055 4.47
(0.97–20.71)
Cannot be estimateda
Gender (female vs. male) 0.132 1.97
(0.82–4.75)
0.114 2.60 (0.79–8.52) 0.855 0.81
(0.09–7.29)
Age (per year) <0.001 1.12
(1.06–1.17)
0.006 1.09 (1.03–1.16) 0.179 1.06
(0.97–1.15)
Renal function (eGFR) (per ml/min) <0.001 0.95
(0.93–0.97)
0.018 0.97 (0.94–0.99) 0.474 0.99
(0.96–1.02)
BMI (per point) 0.602 1.04
(0.91–1.18)
0.318 1.08 (0.93–1.27) 0.964 0.99
(0.76–1.30)
Zwolle Risk Score (per point) <0.001 1.53
(1.40–1.67)
<0.001 1.59 (1.38–1.84) <0.001 1.54
(1.24–1.92)
Zwolle Risk Score > 3 <0.001 9.42
(3.49–25.39)
0.008 4.94
(1.51–16.20)
0.246 2.88
(0.48–17.26)
Log NT-proBNP (per point) <0.001 2.61
(2.00–3.40)
<0.001 9.15
(4.14–20.20)
0.001 4.45
(1.80–10.99)
Delta NT-proBNP (per 100) – – <0.001 1.02 (1.01–1.04) 0.121 0.98
(0.96–1.00)
Multivariate analysis
Log NT-proBNP (per point) <0.001 2.09
(1.59–2.74)
<0.001 6.83
(2.94–15.84)
0.019 3.32
(1.22–9.06)
Zwolle Risk Score (per point) <0.001 1.41
(1.27–1.56)
<0.001 1.34 (1.13–1.57) 0.029 1.35
(1.03–1.77)
aall 5 deaths were in patients randomised to placebo
HR hazard ratio, eGFR estimated glomerular filtration rate, BMI body mass index
tically significant. The analyses were performed in SPSS
version 22 and SAS version 9.3.
Results
A total of 861 patients underwent PPCI. Complete follow-
up was present in 845 patients. Baseline characteristics
are shown in Table 1. The mean age was 62 years and
76% were male. Most patients had low Killip class with
a post PPCI ejection fraction >40%. Mean hospital stay
was 4.89 d.
Baseline NT-proBNP values ranged from 9–33,927 pg/ml
(mean 599 ± 1883 pg/ml) with a median of 138 pg/ml.
At 18–24 h and 72–96 h, NT-proBNP was determined
in 786 and 768 patients respectively, and ranged from
45–20,653 pg/ml (mean 2089 ± 2738 pg/ml, median
1283 pg/ml) and 17–24,119 pg/ml (mean 1618 ± 2556 pg/ml,
median 860 pg/ml) respectively.
The primary endpoint was reached in 21 patients. In
univariate and multivariate analysis, ZRS and NT-proBNP
measured at the different timepoints, but not delta NT-
proBNP, were strongly associated with 30-day mortality
(Table 2).
Predictive value of ZRS and the NT-proBNP
measurements on 30-day mortality
The AUCs for ZRS and NT-proBNP at the different time-
points ranged from 0.74–0.87 and 0.87–0.94 respectively.
The AUC for delta NT-proBNP was relatively low: 0.74
(95% CI 0.48–0.99). Adding NT-proBNP to the ZRS en-
larged the AUCs at all timepoints with the largest area at
18–24 h. In addition, also the highest NRI was acquired by
NT-proBNP at 18–24 h. The integrated discrimination im-
proved significantly after addition of NT-proBNP (Table 3).
Cut-off values and potential early discharge
Optimal cut-off values were defined (sensitivity 100%).
For NT-proBNP at 18–24 h and at 72–96 h, these were
<2500 pg/ml and <1050 pg/ml respectively. Interestingly,
the cut-off value of the ZRS had to be <2. Based on the
serial test combination, we created decision rules imply-
ing that low-risk patients, eligible for early discharge at
48 h after PPCI, had to meet a ZRS <2 or NT-proBNP
<2500 pg/ml, withdrawn at 18–24 h after PPCI (group 1).
Patients eligible for discharge at 96 h after PPCI had to
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Table 3 Prognostic accuracy of Zwolle Risk Score and NT-proBNP in predicting 30-day mortality at the different timepoints
– – AUC 95% CI NRI (%) p value IDI (%) p value
Baseline ZRS 0.87 0.79–0.95 – – – –
NT-proBNP 0.91 0.86–0.96 – – – –
ZRS +
NT-proBNP
0.94 0.90–0.99 9.82 <0.0001 11.39 <0.0001
18–24 h ZRS 0.82 0.70–0.94 – – – –
NT-proBNP 0.94 0.90–0.99 – – – –
ZRS +
NT-proBNP
0.94 0.88–0.99 29.28 <0.0001 17.10 <0.0001
72–96 h ZRS 0.74 0.54–0.94 – – – –
NT-proBNP 0.87 0.72–1.00 – – – –
ZRS +
NT-proBNP
0.87 0.71–1.00 21.93 0.0046 7.46 <0.0001
AUC area under the curve, NRI net reclassification index, IDI integrated discrimination improvement
meet a ZRS <2 or NT-proBNP <1050 pg/ml, withdrawn at
72–96 h after PPCI (group 2).
In group 1, 639 patients met the low-risk criteria and
147 patients were at higher risk (75.6% and 17.3% of the
total study population, respectively).
Up to 48 h, MACE occurred significantly more often in
higher risk patients than in low-risk patients (7 vs. 2 pa-
tients, p < 0.001). Major bleeding occurred in 1 patient in
both groups (0.2% vs. 0.7%, p = 0.34). As a consequence,
637 patients would have been eligible for discharge at 48 h
after PPCI. This accounts for 75% of the total study popu-
lation. Between 48 h and 10 d after PPCI, 10 of these pa-
tients (1.2%) experienced adverse events. MACE occurred
in 7 patients (0.8%) and major bleeding occurred in 4 pa-
tients (0.5%). In 1 patient both events occurred. Therefore,
10 readmissions (1.2%) within 10 d after PPCI would have
been expected (Fig. 2).
In group 2, 500 low-risk patients (59%) could be iden-
tified versus 268 patients (32%) at higher risk, based on
the aforementioned criteria. MACE within 10 d occurred
significantly more often in the higher risk group than in
the lower risk group (11/268 (4%) vs. 4/500 (0.8%), p =
0.003). Major bleeding occurred in 1 patient in the low-
risk group (0.1%) and in 5 patients in the higher risk group
(0.6%). Hence, readmission would have been necessary in
5 patients. The outcome of all screened patients is pre-
sented in Supplementary Fig. 1. The different cut points
and outcome are presented in Supplementary Table 1.
Discussion
Our study demonstrates that NT-proBNP, withdrawn at dif-
ferent timepoints after PPCI, improves prognostication of
the established ZRS and consequently may improve the
scheduling of early hospital discharge.
Although the clinical outcomes in STEMI patients
treated by PPCI have been considerably improved, op-
timising hospital length of stay in these patients is still
challenging.
Recent reports make clear that large groups of patients
can be discharged safely at or within 48 h [6, 9, 10], while
the present guidelines recommend discharge after a mini-
mum of 3 d [1, 2]. In addition, a lot of international vari-
ation in hospital admission duration among low-risk PPCI
patients still exists [3, 17–19]. Assuming that the number of
low-risk PPCI patients worldwide will increase because of
improvement of treatment, there is simultaneously a need
for reduction of health care costs. This highlights the ne-
cessity for easy tools for risk stratification, in which ideally
large proportions of patients could be discharged early. For
this purpose, De Luca et al. developed the ZRS. Impor-
tant variables in this risk model are the success of coronary
reperfusion and the occurrence of heart failure. These and
other early adverse post PPCI events can also be predicted
by NT-proBNP [20–22].
Within this context, NT-proBNP can be considered to be
an overlapping variable. The incremental value of adding
NT-proBNP to established risk factors may be explained
by the fact that biomarker measurement provides more ac-
curate information, without observer variability.
The prognostic significance of the serial changes of
plasma NT-proBNP in STEMI patients has previously
been studied [23–25]. It was shown that NT-proBNP
increases markedly within 24 h. At this timepoint a max-
imum value is reached after successful reperfusion and
then usually decreases, while unsuccessful reperfusion is
associated with increased NT-proBNP values at 48–96 h
[23, 25].
Consequently, the change in NT-proBNP concentration
could also be predictive. In one report, the difference be-
tween NT-proBNP at 72 h and baseline NT-proBNP was
superior to baseline NT-proBNP, but similar to NT-proBNP
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Fig. 2 Feasibility of early
discharge (after 2 d) in 845 PPCI
patients based on ZRS < 2 or
NT-proBNP < 2500 pg/ml at
18–24 h
at 72 h in predicting short-term adverse cardiac events [25].
Interestingly, in our study the change in NT-proBNP was
less predictive and cut-off values were difficult to define,
since some patients had negative changes in NT-proBNP
(or higher values at baseline). However, measurement at
two different timepoints is more laborious and would not
be useful within the context of early discharge.
Based on our decision rule at 48 h after PPCI (ZRS < 2
or NT-proBNP < 2500 pg/ml at 18–24 h), a proportion as
large as 75% of patients could be discharged early. There-
fore NT-proBNP measurement at 18–24 h post PPCI may
optimise length of hospital stay in low-risk patients. Fur-
thermore, this risk strategy can also be applied to patients
in non-intervention hospitals, since many patients are repa-
triated in the first 24 h. Especially this group tends to be
kept in hospital for a longer period of time [26].
Limitations
Several limitations of our study have to be noted. Our study
lacks a validation cohort to validate the serial model of ZRS
and NT-proBNP. Therefore, a future randomised compari-
son of discharge policies should take place. Although NT-
proBNP was measured by protocol in every patient, the
ZRS was calculated afterwards, so this may be considered
retrospective. Although NT-proBNP has also been related
to more cardiovascular risk factors than those used in the
regression analysis, more potential confounders could not
be included because of the number of events. Finally, the
patient population was highly selective since all participants
took part in a randomised trial with aforementioned exclu-
sion criteria.
Conclusion
NT-proBNP at different timepoints improves prognostica-
tion of the ZRS. Particularly at 18–24 h post PPCI, the
Neth Heart J (2017) 25:243–249 249
largest group of patients that potentially could be discharged
early was identified.
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